Monday 19 October 2026
Export THMO’s income statement to Excel — free account
ThermoGenesis Holdings, Inc.
THMO Healthcare Medical Devices
ThermoGenesis Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $9.4 million, down 9.90% from fiscal 2022. Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow THMO
| Older periods | Jun '23 | Sep '23 | Dec '23 | Mar '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.33 | 0.31 | 0.14 | 0.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.91) | (12.07) | (0.65) | (5.74) | |
P/B ratio |
1.21 | 0.93 | 0.00 | 0.00 | |
Price to Tangible BV |
5.52 | 2.48 | 0.00 | 0.00 | |
EV/Sales |
0.83 | 0.85 | 0.91 | 1.14 | |
EV/EBITDA |
8.16 | 3.75 | 10.18 | 0.00 | |
EV/Operating CF |
(2.21) | (2.89) | (2.30) | (3.04) | |
EV/FCF |
(1.55) | (1.84) | (1.57) | (2.39) | |
Quick Ratio |
0.48 | 0.49 | 0.25 | 0.28 | |
Current Ratio |
0.77 | 0.78 | 0.44 | 0.52 | |
Net Debt/EBITDA |
3.64 | (9.82) | 1.93 | (1.42) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.50 | 0.54 | 0.62 | 0.64 | |
Operating CF/Net income |
0.36 | 0.07 | 0.29 | 0.27 | |
Capex/Depreciation |
(1.16) | (0.09) | (0.06) | (0.01) | |
Interest Coverage |
(2.59) | (0.74) | (1.28) | (0.38) | |
Research and Development Expense of Revenue |
16.85% | 12.12% | 13.67% | 7.71% | |
Selling, General and Administrative Expense of Revenue |
79.89% | 76.85% | 77.93% | 56.56% | |
Intangible Assets out of Total Assets |
0.12 | 0.13 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.57% | 0.32% | 0.37% | 0.37% | |
Graham Net Nets |
(2.06) | (1.89) | (7.27) | (2.35) | |
Graham Number |
0.00 | 0.00 | 17.26 | 5.59 | |
Earnings Yield |
(749.08%) | (539.15%) | (1,562.50%) | (713.89%) | |
Free Cash Flow Yield |
(162.14%) | (148.29%) | (411.29%) | (158.45%) | |
Revenue per Share |
0.92 | 0.88 | 1.02 | 0.68 | |
Operating CF per Share |
(0.33) | (0.10) | (0.86) | (0.13) | |
Capex per Share |
(0.24) | (0.07) | (0.08) | 0.00 | |
Free Cash Flow per Share |
(0.56) | (0.17) | (0.94) | (0.13) | |
Cash per Share |
1.79 | 1.60 | 0.84 | 0.29 | |
Shareholders Equity per Share |
1.06 | 1.30 | (1.51) | (0.27) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.06 | 1.30 | (1.51) | (0.27) | |
Free Cash Flow |
(1.40) | (0.43) | (2.23) | (0.52) | |
Working Capital |
(2.53) | (1.96) | (6.58) | (3.95) | |
Capital Expenditures |
(0.59) | (0.18) | (0.19) | (0.02) | |
Net Current Asset Value |
(6.53) | (5.73) | (9.64) | (6.82) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.26 | 0.08 | 0.08 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.54 | 1.21 | 1.41 | 1.05 | |
Average Payables |
0.87 | 0.80 | 0.88 | 0.96 | |
Average Inventory |
4.07 | 3.37 | 2.37 | 2.34 | |
Average Assets |
19.47 | 18.01 | 15.31 | 14.92 | |
Average Common Equity |
4.07 | 3.76 | (0.13) | 1.96 |
Columns are period end dates